Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00300079 · ClinicalTrials.gov registry record · Phase 4

Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension

A Phase 4 study, sponsored by Alcon Research.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target

NCT00300079 is a Phase 4 study that has completed, run by Alcon Research. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00300079, a Phase 4 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target

Study Summary

This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1.0% compared to timolol 0.5% when added to a prostaglandin analogue (PGA) as adjunctive therapy over a 24 hour period in patients with glaucoma or ocular hypertension.

Interventions

  • DRUG brinzolamide 1.0%

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2006-09
Est. Completion 2007-09
Phase Phase 4

Sponsor

Alcon Research

275 total trials

What the Registry Record Tells You About NCT00300079

The ClinicalTrials.gov registry entry for NCT00300079 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon Research, which has 275 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which brinzolamide 1.0% is the first listed.

NCT00300079 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00300079 about?

NCT00300079 is a clinical study titled "Study of the Intraocular Pressure (IOP)-Lowering Efficacy of Azopt 1.0% Compared to Timolol 0.5% in Patients With Glaucoma or Ocular Hypertension". This is a multiple-dose study of the IOP-lowering efficacy of Azopt (brinzolamide) 1.0% compared to timolol 0.5% when added to a prostaglandin analogue (PGA) as adjunctive therapy over a 24 hour period in patients with glaucoma or ocular hypertension.

What is the current status of trial NCT00300079?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2007-09.

What interventions are being tested in trial NCT00300079?

The interventions under investigation include: brinzolamide 1.0% (DRUG).

Who is sponsoring clinical trial NCT00300079?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.